Teva Pharmaceutical Industries TEVA
NYSE TEVA
$36.53 -0.23 (-0.63%)
As of: Sep 9, 2026 · 1:48 PM EDT

Teva Pharmaceutical Industries (TEVA) Change in Receivables (2025 - 2026)

Teva Pharmaceutical Industries' (TEVA) quarterly Change in Receivables came in at $91.0 million in Q2 2026, down 18.02% on a YoY basis from $111.0 million in Q2 2025, and up 216.67% quarter-over-quarter from -$78.0 million in Q1 2026.

Analysis

Teva Pharmaceutical Industries (TEVA) Change in Receivables (2025 - 2026) Analysis & Trends

Teva Pharmaceutical Industries (TEVA) has reported Change in Receivables for 2 consecutive years, with $91.0 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Change in Receivables fell 18.02% year-over-year to $91.0 million; the trailing twelve-month figure through Jun 2026 stood at -$140.0 million (changed N/A YoY), and the FY2025 full-year result was -$173.0 million, down 170.61% from the prior year.
  • Change in Receivables improved to $91.0 million in Q2 2026 per TEVA's latest filing, from -$78.0 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $111.0 million in Q2 2025 and bottomed at -$264.0 million in Q1 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Receivables (Qtr)
1 Teva Pharmaceutical Industries 42.56 Bn 38.90 Bn 2.15 Bn 91.00 Mn
2 Viatris 19.13 Bn 18.24 Bn 1.46 Bn 126.50 Mn
3 Dr Reddys Laboratories 9.86 Bn 9.69 Bn 396.53 Mn -
4 Amneal Pharmaceuticals 5.46 Bn 5.33 Bn 334.51 Mn 169.78 Mn
5 Bausch Health Companies 2.37 Bn 528.25 Mn 2.10 Bn 70.00 Mn
6 Alvotech 1.51 Bn 1.37 Bn 2.56 Mn 1.24 Mn
7 Ani Pharmaceuticals 1.49 Bn 1.13 Bn 165.89 Mn 19.08 Mn
8 Amphastar Pharmaceuticals 992.90 Mn 702.78 Mn 93.47 Mn -2.98 Mn
9 Fennec Pharmaceuticals 411.43 Mn 370.18 Mn 17.15 Mn -
10 RedHill Biopharma 181.39 Mn 181.39 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 91.00 Mn
Mar 31, 2026 -78.00 Mn
Jun 30, 2025 111.00 Mn
Mar 31, 2025 -264.00 Mn